

Financial Snapshot

Ticker: (NASDAQ: PIRS)
 Share price: \$4.73 (as of 06/24/19)
 Market Cap: \$233.00M (as of 06/24/19)
 Cash and investments: \$110.8M (1Q2019)
 Common Shares Outstanding: 50.9M

Corporate Headquarters

Pieris Pharmaceuticals, Inc.
 255 State Street, 9th floor
 Boston, MA 02109
 +1 (857) 246 8998

Munich Site

Pieris Pharmaceuticals GmbH
 Lise-Meitner-Strasse 30
 85354 Freising
 Germany
 +49 (0) 8161 1411 400

For more information:

info@pieris.com

www.pieris.com

For business development

or partnering inquiries:

bd@pieris.com

For investor relations

inquiries:

Maria Kelman, Director of

Investor Relation:


kelman@pieris.com

Company Overview

Pieris Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops Anticalin[®]-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes inhaled Anticalin proteins to treat respiratory diseases, immuno-oncology multi-specifics (tumor-targeted costimulatory approach and dual-checkpoint inhibitors), and a half-life-optimized Anticalin protein to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of protein therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies.

Anticalin[®] Proteins


Anticalin proteins are engineered lipocalins, or human proteins that naturally bind, store, and transport a wide spectrum of molecules. Our libraries of more than 100 billion different Anticalin proteins can bind to virtually any target of interest.



Unique Formatting Options • Potent Multi-Target Engagement

Advantages of Anticalin Proteins

- Formatting flexibility for multispecific drugs
- Alternative delivery routes (e.g. inhaled)
- Potential for more cost-effective prokaryotic expression
- Tunable pharmacokinetics to match biological need
- Dominant patent position and positive FTO position



February 2018:

Multi-program strategic alliance developing targeted bispecific immuno-oncology treatments for solid tumors and blood cancers

- \$30M upfront
- ~\$1.2B in milestone potential



May 2017:

Multi-program strategic co-development alliance to develop inhaled biologics for respiratory diseases; includes

PRS-060 and 4 additional programs

- \$57.5M upfront and 2017 milestone
- ~\$2.1B in milestone potential



January 2017: Multi-program strategic co-development immuno-oncology alliance; includes PRS-332 and 4 additional programs

- \$31M upfront
- ~\$1.8B in milestone potential

Pipeline

RESPIRATORY							
CANDIDATE	TARGETS	PARTNER	COMMERCIAL RIGHTS	DISCOVERY	PRECLINICAL	PHASE I	PHASE II
PRS-060	IL4-R α	AstraZeneca	Pieris Worldwide Profit-Share Option				
Proprietary Programs	n.d.	n/a	Pieris Worldwide				
AstraZeneca Programs*	n.d.	AstraZeneca	Pieris Worldwide Profit-Share Option*				
*4 additional respiratory programs (2 active, 2 forthcoming) in collaboration with AstraZeneca, 2 of which carry co-development and co-commercialization options for Pieris							
IMMUNO-ONCOLOGY							
CANDIDATE	TARGETS	PARTNER	COMMERCIAL RIGHTS	DISCOVERY	PRECLINICAL	PHASE I	PHASE II
PRS-343	HER2/4-1BB	n/a	Pieris Worldwide				
	+ Anti-PD-L1	n/a					
PRS-344	PD-L1/4-1BB	Servier	Pieris U.S. Rights				
Servier Programs†	n.d.	Servier	Pieris U.S. Option†				
Proprietary IO Programs	n.d.	n/a	Pieris Worldwide				
Seattle Genetics Programs‡	n.d.	Seattle Genetics	Pieris U.S. Option‡				
†4 additional IO bispecific programs in collaboration with Servier, with Pieris retaining US rights for 2 of 5 programs							
‡3 bispecific programs (1 active, 2 forthcoming) in collaboration with Seattle Genetics, with Pieris retaining US rights for 1 program							
OTHER DISEASE AREAS							
CANDIDATE	TARGETS	PARTNER	COMMERCIAL RIGHTS	DISCOVERY	PRECLINICAL	PHASE I	PHASE II
PRS-080	Hepcidin	ASKA	Major Markets Ex-ASKA Territories				

Program Highlights

PRS-060 – (IL-4R α Antagonist)

- Lead respiratory program targeting IL-4R α for asthma
- Differentiated from injectable antibodies against IL-4 and IL-13 through inhaled delivery directly to the lungs, potentially offering more convenient delivery, a significant cost of goods advantage and an expanded patient population over systemic antibodies
- Being developed in a collaboration with AstraZeneca
- Phase 1a showed drug to be safe and well-tolerated in healthy volunteers, with no SAEs, a favorable PK profile and robust target engagement
- Phase 1b data, including fractional exhaled nitric oxide (FeNO) reduction, to be reported at upcoming medical meeting

PRS-343 – (4-1BB/HER2 Bispecific)

- Bispecific drug candidate with 4-1BB-targeting Anticalin proteins (key costimulatory target for tumor-specific T cells) and a HER2-targeting antibody (validated expression in bladder, gastric, breast cancer and others)
- Demonstrated strong tumor growth inhibition and lymphocyte infiltration *in vivo*, while avoiding undesirable peripheral T-cell activation
- Currently in Phase 1 monotherapy trial and in Phase 1 combination trial with PD-L1 for HER2+ solid tumors

PRS-344 – (4-1BB/PD-L1 Bispecific)

- Bispecific drug candidate with 4-1BB-targeting Anticalin proteins (enhancing mitochondrial function in T cells) and a PD-L1-targeting antibody, a target combination that has demonstrated robust preclinical anti-tumor activity
- Being developed in a collaboration with Servier; Pieris has opted-in for U.S. commercial rights
- Planned IND in 2019

Management Team

Stephen S. Yoder, JD, President & Chief Executive Officer
Louis Matis, MD, SVP & Chief Development Officer
Allan Reine, MD, SVP & Chief Financial Officer
Shane Olwill, PhD, VP, Development & Head of Immuno-Oncology
Christine Rothe, PhD, VP, Head of Discovery & Alliance Management
Mary Fitzgerald, PhD, VP, Respiratory Medicine
Eckhard Niemeier, VP, Business Development
Ahmed Mousa, JD, VP & General Counsel
Ingmar Bruns, MD, PhD, VP, Clinical Development
Tom Bures, VP, Finance
Frank Vollmering, VP, Talent & Organizational Development (HR)

Board of Directors

Ann Barbier, MD, PhD (CMO, Translate Bio)
Jean-Pierre Bizzari, MD (Former EVP, Celgene)
James Geraghty, (Former Executive, Sanofi and Genzyme), Chairman
Christopher Kiritsy (Founder and Managing Member, Precision Capital)
Peter Kiener, DPhil (Former Executive, Sucampo and BMY)
Steven Prelack (SVP & COO, VetCor)
Michael Richman (CEO, NextCure)
Matthew L. Sherman, DPhil (Former Executive, Acceleron)
Stephen S. Yoder, JD (President & CEO, Pieris)